@article {1435410,
	title = {Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies},
	journal = {Ocul Immunol Inflamm},
	year = {2019},
	month = {2019 Apr 23},
	pages = {1-6},
	abstract = {PURPOSE: To report the clinical features, severity, and management of ocular immune-related adverse events (irAEs) in the setting of immune checkpoint inhibitor therapy for metastatic malignancies. METHODS: Retrospective chart review at three tertiary ophthalmology clinics. Electronic medical records were reviewed between 2000 and 2017 for patients with new ocular symptoms while undergoing checkpoint inhibition therapy. RESULTS: Eleven patients were identified. Ocular irAEs ranged from keratoconjunctivitis sicca to Vogt-Koyanagi-Harada-like findings. Average timing of irAEs from starting checkpoint inhibitor therapy was 15.7 weeks. Ocular inflammation was successfully controlled with corticosteroids in most cases, however three patients discontinue treatment as a result of ocular inflammation with decreased visual acuity, two discontinued due to progression of metastatic disease, and one discontinued due to severe systemic irAEs. CONCLUSION: We found a wide spectrum of ocular irAEs associated with immune checkpoint inhibitors. In most cases, ocular AEs did not limit ongoing cancer treatment.},
	issn = {1744-5078},
	doi = {10.1080/09273948.2019.1583347},
	author = {Noble, Carl W and Gangaputra, Sapna S and Thompson, Ian A and Yuan, Amy and Apolo, Andrea B and Lee, Jung-Min and Papaliodis, George N and Kodati, Shilpa and Bishop, Rachel and Magone, M Teresa and Sobrin, Lucia and Sen, H Nida}
}
